TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-11

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I trial studies the side effects and best dose of trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) when given together with radiation therapy in treating patients with rectal cancer that has come back, spread to other places in the body, or cannot be removed by surgery. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving TAS-102 with radiation therapy may kill more tumor cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy

NCT05965531

Rectal Cancer

RECRUITING PHASE2

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

NCT04104139

Rectal Adenocarcinoma Stage IIA Rectal Cancer AJCC v8 Stage IIB Rectal Cancer AJCC v8 +4 more

ACTIVE_NOT_RECRUITING PHASE1

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer

NCT03223779

Colorectal Cancer

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer

NCT07090031

EFS pCR Rate

ACTIVE_NOT_RECRUITING PHASE2

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

NCT06850090

Rectal Cancer Rectal Cancer Patients

NOT_YET_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose and dose-limiting toxicity of TAS-102 when administered in combination with concurrent radiation therapy in patients with locally recurrent or metastatic rectal cancer.

SECONDARY OBJECTIVES:

I. To determine the overall response rate (ORR) to concurrent TAS-102 and radiation therapy in patients with locally recurrent or metastatic rectal cancer.

II. To determine the progression-free survival (PFS) in patients with locally recurrent or metastatic rectal cancer who receive concurrent TAS-102 and radiation therapy.

III. To determine the overall survival (OS) in patients with locally recurrent or metastatic rectal cancer who receive combined TAS-102 and radiation therapy.

IV. To determine quality of life (QoL) among patients with locally recurrent or metastatic rectal cancer who receive concurrent TAS-102 and radiation therapy.

V. To determine the number of patients who are able to undergo surgical resection following concurrent treatment with TAS-102 and radiation therapy. Of this subset of patients, the investigators will assess rates of pathologic complete response (pCR), tumor regression grade (TRG) and rates of R0 resection.

OUTLINE: This is a dose-escalation study of trifluridine/tipiracil hydrochloride combination agent TAS-102.

Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally (PO) twice daily (BID) and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 4-6 weeks, and at 3 and 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Adenocarcinoma Recurrent Rectal Carcinoma Stage IV Rectal Cancer AJCC v7 Stage IVA Rectal Cancer AJCC v7 Stage IVB Rectal Cancer AJCC v7

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (TAS-102, radiation therapy)

Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Quality-of-Life Assessment

Intervention Type OTHER

Ancillary studies

Radiation Therapy

Intervention Type RADIATION

Undergo radiation therapy

Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Intervention Type DRUG

Given PO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quality-of-Life Assessment

Ancillary studies

Intervention Type OTHER

Radiation Therapy

Undergo radiation therapy

Intervention Type RADIATION

Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

Given PO

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Quality of Life Assessment Cancer Radiotherapy Irradiate Irradiated irradiation Radiation Radiotherapeutics Radiotherapy RT Therapy, Radiation Lonsurf TAS-102 Trifluridine/Tipiracil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological or cytological confirmation of locally recurrent or metastatic rectal adenocarcinoma

* Note: Patients with locally recurrent/persistent disease within the pelvis after primary therapy (chemotherapy, surgery, and/or radiotherapy) are eligible
* Note: Patients who have had prior pelvic radiotherapy with a total dose of =\< 54 Gy are eligible
* Note: Patients with or without metastatic disease (excluding untreated central nervous system \[CNS\] metastasis), with primary pelvic disease or pelvic recurrence are eligible
* Note: Patients with pelvic disease that is potentially resectable or unresectable are eligible
* Measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
* Expected life expectancy \>= 12 weeks
* Obtained =\< 14 days prior to registration: Absolute neutrophil count (ANC) \>= 1500/mm\^3
* Obtained =\< 14 days prior to registration: Platelet count \>= 100,000/mm\^3
* Obtained =\< 14 days prior to registration: Hemoglobin \>= 9.0 g/dL
* Obtained =\< 14 days prior to registration: Total bilirubin =\< 1.5 x upper limit of normal (ULN) (in patients with well-documented Gilbert's syndrome and the total bilirubin is grade 1, then direct bilirubin value must be =\< 1.0 mg/dL)
* Obtained =\< 14 days prior to registration: Aspartate transaminase (AST) =\< 2 x ULN (=\< 5 x ULN for patients with liver involvement)
* Obtained =\< 14 days prior to registration: Alanine aminotransferase (ALT) =\< 2 x ULN (=\< 5 x ULN for patients with liver involvement)
* Obtained =\< 14 days prior to registration: Alkaline phosphatase =\< 3 x ULN
* Obtained =\< 14 days prior to registration: Creatinine =\< 1.5 x ULN OR
* Obtained =\< 14 days prior to registration: Calculated creatinine clearance must be \>= 45 ml/min using the Cockcroft-Gault formula
* Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only; Note: patients must agree to adequate birth control during the study and for up to 6 months after discontinuation of study medication
* Patients must be able to take medications orally (i.e. no feeding tube)
* Provide written informed consent
* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
* Able to complete questionnaires by themselves or with assistance

Exclusion Criteria

* Primary resectable rectal cancer
* Prior treatment with TAS-102
* Chemotherapy or immunotherapy =\< 28 days prior to registration
* Radiation therapy =\< 28 days prior to registration; Note: patients with prior pelvic radiation therapy \> 54 Gy are ineligible
* Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment
* Other concurrent chemotherapy, immunotherapy, or any ancillary antitumor therapy considered investigational (utilized for a non-Food and Drug Administration \[FDA\]-approved indication and in the context of a research investigation)
* Untreated CNS or leptomeningeal metastasis

* Note: CNS or leptomeningeal disease must be stable for \>= 3 months prior to registration
* History of seizure disorder
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Ascites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks prior to registration
* Intestinal obstruction, uncontrolled gastrointestinal hemorrhage, pulmonary fibrosis, renal failure, liver failure, or cerebrovascular disorder
* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or hepatitis B or C
* Patients with autoimmune disorders or history of organ transplantation who require immunosuppressive therapy
* History of myocardial infarction =\< 12 months prior to registration, severe/unstable angina, systematic congestive heart failure (CHF) New York Heart Association classification III or IV or CHF requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
* Major surgery =\< 4 weeks prior to registration (the surgical incision should be fully healed prior to drug administration or radiation therapy)
* Any of the following:

* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No